NCT03695419

Brief Summary

According to the United Nations Office on Drugs and Crime \[UNODC\] World Drug Report, the annual prevalence of drug use seemed to be stable for the past few years. However, new psychoactive substances (NPS) have increased drastically in both supply and demand.Many NPS were discovered at the same time as other drugs, and it was simply, for whatever reasons, these other drugs became popular. The majority of these substances are chemicals produced by tweaking or altering the molecular structure of previous well-known psychoactive agents such as cannabis, cocaine, methylenedioxymeth-amphetamine (or MDMA, commonly known as ecstasy), and lysergic acid diethylamide (or LSD), which are being sold as "legal highs," "research chemicals," "herbal highs," "party pills," or "plant food" in an attempt to stay ahead of the law prohibiting the sale and use of psychoactive drugs.Substance abuse rates in Egypt have hit 10%, or double the global average. Tramadol is the most abused substance, followed by cannabis and heroin.In the past two years, two new drugs - known as Strox and Voodoo - have hit the Egyptian market.Voodoo is a combination of an aromatic plant, like marjoram or incense, which is infused with a synthetic cannabinoid that is up to 100 times as powerful as natural marijuana. Shabu is another name for methamphetamine hydrochloride, also known as crystal meth. Meth is a highly addictive stimulant that causes its user irreversible harm, physically and mentally. Pregabalin is increasingly being reported as possessing a potential for misuse.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2019

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 4, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

October 5, 2018

Status Verified

October 1, 2018

Enrollment Period

1 year

First QC Date

September 29, 2018

Last Update Submit

October 3, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • the prevalence of new psychoactive substance abuse among outpatient of addiction management clinic and patients admitted to addiction management unit of neurology and psychiatry department at Assiut university hospital.

    All participant will subjected to the following: Special sheet designed for the study in department of neurology and psychiatry at Assiut University hospital asking about spychoactive substance use regarding to type, amount, duration,cause of use, and cause for stoppage. Addiction severity index Urinary drug screen

    2years

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The study group comprised of Egyptians participants. Their age ranged between 18-60 years old, and both men and women are included. They fulfilled the criteria for substance abuse according to DSM-5 criteria. They were selected from the outpatient of addiction management clinic (either admitted to addiction management unit or not) of psychiatric unit of neurology and psychiatry department at Assiut university hospital.

You may qualify if:

  • Patients diagnosed as substance dependence according to DSM-5 criteria.
  • Aged between 18-60 years of both sex.
  • Acceptance to participate in the study.

You may not qualify if:

  • Chronic general medical conditions.
  • Patients refused to participate at study
  • History or current bipolar or psychotic disorder.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Bozkurt M, Karabulut V, Evren C, Seker M, Kan H. Intravenous Abuse of Tropicamide in Opioid Use Disorder: Presentation of 2 Cases. Subst Abus. 2015;36(2):170-3. doi: 10.1080/08897077.2014.924465. Epub 2014 Jun 3.

    PMID: 24892477BACKGROUND

MeSH Terms

Conditions

Behavior, Addictive

Condition Hierarchy (Ancestors)

Compulsive BehaviorImpulsive BehaviorBehavior

Study Officials

  • Romany H Gabrah

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Esraa A Abdel-regal, Doctor

CONTACT

Romany H Gabrah, Lecurer

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Princible investigator

Study Record Dates

First Submitted

September 29, 2018

First Posted

October 4, 2018

Study Start

January 1, 2019

Primary Completion

January 1, 2020

Study Completion

December 30, 2021

Last Updated

October 5, 2018

Record last verified: 2018-10